Short Term Buy Call For Aurobindo Pharma

Short Term Buy Call For Aurobindo PharmaTechnical analyst Kunal Sarogi has maintained 'buy' rating on Aurobindo Pharma Ltd stock with a stop loss of Rs 1200.

According to analyst, the investors can buy the stock with a target of Rs 1370.

Today, the stock of the company opened at Rs 1249.95 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1349 and a low of Rs 786.25 on BSE.

Current EPS & P/E ratio stood at 81.76 and 15.22 respectively.

Aurobindo Pharma has recorded an increase of 92.19% in its consolidated net profit, which stood at Rs 1,983.20 million for the three month period ended Sept 2010 as against Rs 1,031.90 million for the same period of last year.

The company's total income surged 25.45% to Rs 11,232 million for the period ended Sept 2010 from Rs 8,953.40 million July-September period ended Sept 2009.

Hyderabad-based Aurobindo Pharma will be inking a deal with Pfizer yet again for digging into the strong-growing Japanese and Korean generics market.

Aurobindo Pharma will shortly sign pact to this effect.

Now, Aurobindo has a strategic pact with Pfizer to sell around 100 products in geographies such as the US, Europe and other rising market regions.

The Japanese market is a highly-shaped one, but provides a market share of $80 billion.